GLAUKOS Corp

GKOS 10-Q · Q1 2026
API behind this page

GKOS Q1 2026 request

Playground key active
Request URL /api/financials?ticker=GKOS&year=2026&quarter=1
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q1 2026 Q1 2025 YoY
Revenue 150,571 106,664 +41.2%
Show Product Lines breakouts
Corneal Health 21,310 18,527 +15.0%
Corneal Health · Non Us 2,419 2,585 -6.4%
Corneal Health · US 18,891 15,942 +18.5%
Glaucoma 129,261 88,137 +46.7%
Glaucoma · Non Us 35,808 29,009 +23.4%
Glaucoma · US 93,453 59,128 +58.1%
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies 150,571 106,664 +41.2%
Show Geography breakouts
Non Us 38,227 31,594 +21.0%
US 112,344 75,070 +49.7%
Cost of Revenue 33,339 24,316 +37.1%
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies 33,339 24,316 +37.1%
Gross Profit 117,232 82,348 +42.4%
Selling, General & Administrative 92,943 70,673 +31.5%
Research And Development Expense Excluding Acquired In Process Cost 44,145 32,353 +36.4%
Operating Expenses 137,088 103,026 +33.1%
Operating Income -19,856 -20,678 +4.0%
Interest And Other Income 2,431 3,076 -21.0%
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies 2,431 3,076 -21.0%
Interest Expense -1,125 -1,163 +3.3%
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies -1,125 -1,163 +3.3%
Other Non-Operating Income (Expense) -749 945 -179.3%
Non-Operating Income (Expense) 557 2,858 -80.5%
Income Before Taxes -19,299 -17,820 -8.3%
Income Tax Expense (Benefit) 484 326 +48.5%
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies 484 326 +48.5%
Net Income -19,783 -18,146 -9.0%
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies -19,783 -18,146 -9.0%
EPS (Basic) -0.34 -0.32 -6.3%
EPS (Diluted) -0.34 -0.32 -6.3%
Wtd Avg Shares (Basic) 58,022 56,637 +2.4%
Wtd Avg Shares (Diluted) 58,022 56,637 +2.4%
Research & Development (Q) — — —
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies 28,971 22,922 +26.4%
Sales & Marketing (Q) — — —
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies 46,289 34,443 +34.4%
General & Administrative (Q) — — —
Show Business Segments breakouts
Development and Commercialization of Ophthalmic Therapies 46,654 36,230 +28.8%
Comprehensive Income -20,443 -18,156 -12.6%

Balance Sheet

Balance Sheet
Metric Q1 2026 Q1 2025 YoY
Current Assets
Cash & Cash Equivalents 104,249 — —
Available For Sale Securities Debt Securities 172,436 184,444 -6.5%
Show Financial Instrument breakouts
Asset Backed Securities 13,626 6,333 +115.2%
Bank Time Deposits 47,175 — —
Commercial Paper Not Included With Cash And Cash Equivalents 1,832 — —
Corporate Debt Securities 36,740 10,918 +236.5%
US Treasury Securities 73,063 164,175 -55.5%
Accounts Receivable 119,691 71,531 +67.3%
Inventory 62,384 59,460 +4.9%
Prepaid Expenses & Other Current Assets 26,993 14,857 +81.7%
Total Current Assets 485,753 444,544 +9.3%
Non-Current Assets
Restricted Cash And Cash Equivalents Noncurrent 3,834 4,733 -19.0%
Property, Plant & Equipment 112,432 — —
Show Geography breakouts
Non Us 273 — —
US 112,159 — —
Operating Lease Right-of-Use Assets 31,025 32,176 -3.6%
Goodwill 66,710 — —
Deposit Assets And Other Assets Noncurrent 21,744 22,699 -4.2%
Total Assets 893,326 966,178 -7.5%
Intangible Assets 125,828 — —
Show Finite Lived Intangible Assets By Major Class breakouts
Developed Technology And Customer Relationships [Member] 16,069 — —
Epioxa Developed Technology 103,943 — —
Leases Acquired In Place 255 — —
Licensing Agreements 4,619 — —
Photrexa Developed Technology 942 — —
Show Type Of Arrangement breakouts
License Agreement with Celanese 4.6 — —
Other Assets
Finance Lease Right Of Use Asset 38,800 41,213 -5.9%
Intangible Assets Net Excluding Goodwill 133,028 — —
Current Liabilities
Accounts Payable 19,153 15,825 +21.0%
Accrued Liabilities 70,262 52,704 +33.3%
Total Current Liabilities 89,415 68,529 +30.5%
Non-Current Liabilities
Operating Lease Liabilities 35,313 36,321 -2.8%
Finance Lease Liability Noncurrent 67,743 69,159 -2.0%
Deferred Tax Liabilities 441 6,918 -93.6%
Other Non-Current Liabilities 29,486 21,292 +38.5%
Total Liabilities 222,398 202,219 +10.0%
Stockholders' Equity
Common Stock 58 57 +1.8%
Additional Paid In Capital Common Stock 1,621,272 1,525,014 +6.3%
Accumulated Other Comprehensive Income 2,643 2,605 +1.5%
Retained Earnings -952,913 -763,585 -24.8%
Treasury Stock Common Value -132 -132 0.0%
Total Stockholders' Equity 670,928 763,959 -12.2%
Total Liabilities & Equity 893,326 966,178 -7.5%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q1 2026 YTD Q1 2025 YoY
Operating Activities
Net Income -19,783 -18,146 -9.0%
Show Equity Components breakouts
Retained Earnings -19,783 -18,146 -9.0%
Depreciation 2,909 2,651 +9.7%
Amortization Of Intangible Assets 8,888 5,576 +59.4%
Operating Lease Right Of Use Asset Amortization Expense 1,085 1,078 +0.6%
Gain Loss On Sale Of Property Plant Equipment 103 6 +1616.7%
Stock-Based Compensation 19,144 12,986 +47.4%
Foreign Currency Transaction Gain Loss Unrealized 574 1,397 -58.9%
Amortization Of Discount On Short Term Investments -187 -1,149 +83.7%
Increase Decrease In Others Accrued Liabilities -2,249 -1,091 -106.1%
Provision For Doubtful Accounts 823 1,367 -39.8%
Change in Accounts Receivable -12,459 -12,316 -1.2%
Change in Inventory 832 -1,668 +149.9%
Increase Decrease In Prepaid Expense And Other Current Assets -2,985 -2,339 -27.6%
Increase Decrease In Accounts Payable And Accrued Liabilities -10,192 -6,729 -51.5%
Increase Decrease In Other Noncurrent Assets 971 -134 +824.6%
Net Cash from Operations -12,526 -18,521 +32.4%
Depreciation & Amortization 11,797 8,227 +43.4%
Show Geography breakouts
Non Us 11 12 -8.3%
US 11,786 8,215 +43.5%
Investing Activities
Payments To Acquire Marketable Securities -31,353 -74,743 +58.1%
Proceeds From Sale And Maturity Of Marketable Securities 46,575 40,878 +13.9%
Capital Expenditures -3,959 -1,938 -104.3%
Payments For Investment In Company Owned Life Insurance Policy -759 -395 -92.2%
Net Cash from Investing 10,504 -36,948 +128.4%
Financing Activities
Proceeds From Stock Options Exercised 19,330 4,082 +373.5%
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans 2,381 2,961 -19.6%
Tax Withholding for Share Compensation -5,638 -4,845 -16.4%
Finance Lease Principal Payments -304 -248 -22.6%
Net Cash from Financing 15,769 1,950 +708.7%
Supplemental
Income Taxes Paid 379 276 +37.3%
Interest Paid 1,042 1,058 -1.5%
Unpaid Capital Expenditures 863 502 +71.9%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations -311 -1,855 +83.2%
Net Change in Cash 13,436 -55,374 +124.3%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 108,083 118,985 -9.2%

Values in thousands USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key